Ruxolitinib exerts immunosuppressive activity that may increase the risk of infectious complications.
| I N TR ODU C TI ON
Ruxolitinib is an oral inhibitor of JAK1 and JAK2, which is approved for the treatment of intermediate-and high-risk myelofibrosis (MF) and high-risk polycythemia vera (PV). [1] [2] [3] [4] Ruxolitinib selectively inhibits the proliferation of JAK2-driven Ba/F3 cells and these effects are correlated with decreased levels of phosphorylated JAK2 and of signal transducer and activator of transcription 5 (STAT5). 5, 6 Treatment with ruxolitinib decreases constitutional symptoms and spleen size in Philadelphia-negative myeloproliferative neoplasms (MPN) 7 .
Recently, several case reports of opportunistic infections in MPN patients on ruxolitinib have been published. 8 Increasing evidence suggests that ruxolitinib may exert substantial immunosuppressive activity.
In particular, ruxolitinib was shown to modulate dendritic cell (DC) function resulting in impaired CD41 and CD81 T-cell priming both in vitro and in vivo. 9, 10 In addition, inhibition of JAK1 impairs cytokine production, 11 which may result in reduced control of silent infections and increased risk of reactivation of potentially life-threatening opportunistic infections. 8, 12 Based on this background, we performed a systematic review and a meta-analysis of interventional phase III and observational post-marketing studies assessing safety and efficacy of ruxolitinib in MPN, with the following aims: (i) to compare the incidence of infections in ruxolitinib-treated and non-ruxolitinib-treated patients during active treatment and follow-up; (ii) to assess the type and severity of infectious complications in these patients.
| M ET HOD S

This systematic review was performed according to Preferred Reporting
Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. 13 
| Search strategy
Using MEDLINE and EMBASE electronic databases (from 2005 to July 2017), we attempted to identify all studies that reported infectious events during ruxolitinib therapy in MPN. As several case reports of opportunistic infections in MPN patients on ruxolitinib have been published, we developed two search strategies with the aim to identify: (i) "phase 4 clinical trial"; (ii) "ruxolinitib," and "infection." Search strategies were developed without any language restriction and run on www.
embase.com. We supplemented our search by manually reviewing the reference list of all retrieved articles. We also searched on the www.
clinicaltrials.gov to identify unpublished trials.
| Study selection
Two reviewers (FL and AS) performed study selection. Studies were considered potentially eligible for this systematic review when they met the following criteria: (i) studies were phase III RCTs or observational post-marketing studies, including case series and case reports;
(ii) infectious events were reported as adverse events. In case data from a RCT were reported in more than one publication, we extracted relevant data from the most recent paper. We excluded studies in which ruxolitinib was associated with other treatments, in particular immunomodulatory drugs (interferon, lenalidomide, pomalidomide, 5-azacytidine) and conference abstracts for limiting the risk of bias.
| Data extraction
Two reviewers (FL and AS) extracted data on study details (year of publication, design), population characteristics (patients' number, age and sex), type of intervention and comparison (when present), duration of treatment, infectious events and duration of follow-up.
As infectious events were not systematically reported in phase III studies, markers of infections, such as fever, were also recorded. All outcomes occurring during active treatment and during follow-up period were recorded. 
| Risk of bias assessment
| RE S U L TS
| Study identification and selection
The process of study selection is outlined in Supporting Information Figure S1 . We identified 363 potentially relevant studies with the first electronic search strategy and 466 studies with the second search.
A total of 783 studies were excluded, based on title and abstract, because they were duplicate publications or did not meet our predefined inclusion criteria, leaving 47 studies for more detailed assessment.
Eight papers were excluded for the following reasons: pooled analysis (n 5 1), follow-up of phase I or II trial (n 5 1), sub-analyses (n 5 2), data on extension phase study with a shorter follow-up (n 5 2), redundant publications (n 5 2). were included also in phase III studies and 1 in phase IV study) 12, were included in this systematic review.
| Phase III RCTs 3.2.1 | Study characteristics
The main characteristics of the included phase III RCTs are summarized in Supporting Information Table S1 . Two studies (COMFORT I and 
| Risk of bias
The assessment of bias risk based on Cochrane criteria 14 is summarized in Supporting Information Figure S2 . None of the included studies was at low risk of bias. In particular, no studies systematically reported infectious events as pre-specified secondary outcome. (Table 1b) .
| Ruxolitinib-associated infections
More data on infections were available in the extended phase publications. [20] [21] [22] Main data are reported in (Figure 1b ).
Other pooled analyses did not reveal statistically significant differences (Table 2b ).
3.3 | Phase IV post-marketing studies
| Study characteristics
Six phase IV post-marketing studies [23] [24] [25] [26] [27] [28] were analysed: their main characteristics are reported in Table 3 . All studies included patients with MF, who received oral ruxolitinib at doses ranging between 5 mg and 50 mg daily. Median duration of treatments was between 11 and 23 months.
| Risk of bias
None of the studies fulfilled the pre-defined requirements to be considered at low risk of bias (Supporting Information Table S2 ).
| Ruxolitinib associated infections
In the JUMP study 23 involving 1144 patients, the most frequent infectious complications were: herpes zoster (8%), bronchitis (6.1%) and urinary tract infections (6%). No cases of tuberculosis were reported ( were diagnosed in 16 patients (16.3%), 10 of which were bronchopneumonia. Only one case of herpes zoster reactivation has been described, whereas no cases of tuberculosis were reported. In a study of ruxolitinib in Japanese patients with MF, herpes zoster infections were reported in 2 patients (3.9%), pneumonia in 4 (8%), urinary tract infection in 1 (2%) and sepsis in 1 (2%). 27 Finally, in a very small study of 10 patients in Taiwan, one hepatitis B reactivation was reported. 25 
| Case reports
A total of 31 patients with ruxolitinib-associated infections were reported in published case reports (Supporting Information Table S3 ). 
| D I SCUSSION
To the best of our knowledge, this is the first systematic review and meta-analysis that has been performed with the primary aim to evaluate the incidence and severity of infectious complications in MPN patients treated with ruxolitinib. Available evidence is insufficient to accurately estimate the risk of infections in ruxolitinib-treated patients, but suggests that the incidence of opportunistic and viral infections in ruxolitinib-treated patients may be clinically relevant. 12, 30, 36, 37, 44, 48, 50 Our analysis provides researcher, editors and clinicians with impor- ; ii) it has been associated with down-regulation of Tregs and impairment of the dendritic cell function 8, 10, 57, 58 ; iii) it impairs natural killer (NK) cell function in MPN patients. 59 These immunosuppressive properties may play a role in the risk of infections in patients on treatment with ruxolitinib, although the exact relationship between the effects on immune function and the incidence of infections remains to be elucidated.
Strengths of our systematic review include the careful search of the literature and the inclusion of different type of studies. Conversely, our study has some limitations. First, our analysis might have underestimated the risk of infections, because infectious events were not systematically reported by all authors. We assumed that studies in which no events were reported no events occurred, although we deem that this is an unlikely possibility. Second, raw estimates may be biased because we considered only studies reporting the outcomes.
In conclusion, our systematic review suggests that a careful assessment of the infective risk is necessary before starting ruxolitinib, to identify patients who might benefit from antimicrobial prophylaxis. Our findings remind the clinical community of the importance for postmarketing surveillance and close monitoring for safety of patients receiving these drugs. Well-designed studies are warranted to correctly evaluate ruxolitinib-associated infection risk to define a solid evidencebased antimicrobial prophylactic strategy.
